ReviewJournal of clinical medicine2022
Anticoagulant Therapy in Patients with Antiphospholipid Syndrome.
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Pooled it
- Use of Anticoagulants as a Supportive Measure in Pulmonary Hypertension: A Narrative Review.Tuberculosis and respiratory diseases · 2026Article
- Secondary anticoagulation prophylaxis for children with antiphospholipid syndrome: a systematic review and meta-analysis.Blood advances · 2026Article
- Polycythemia Vera, Thrombophilia, CTEPH, Cerebral Venous Sinus Thrombosis and Vertebral Artery Occlusion: A Case-Illustrated Narrative Review of Competing Thrombotic and Hemorrhagic Risks.Life (Basel, Switzerland) · 2026Article
- Cost-Effectiveness Analysis of Patient Self-Management of Warfarin Among Patients With Non-Valvular Atrial Fibrillation.Pharmacotherapy · 2026Article
- Acute Finger Ischemia Evaluated With Point-Of-Care-Ultrasound and Diagnosed With Concurrent Polycythemia Vera, Antiphospholipid Syndrome, and Tobacco Use.Clinical case reports · 2026Article
- Avascular necrosis in antiphospholipid syndrome: pathophysiology, risk factors, and management.Clinical rheumatology · 2026Review
- Immunopathogenesis of accelerated atherosclerosis in systemic lupus erythematosus: from innate and adaptive dysregulation to clinical implications.Frontiers in immunology · 2026Review
- Review
- Expert Review of the Strategies to Optimize Long-Term Outcomes After Coronary Artery Bypass Grafting.Reviews in cardiovascular medicine · 2025Review
- Machine learning for predicting thrombotic recurrence in antiphospholipid syndrome.Research and practice in thrombosis and haemostasis · 2025Article
- Evaluation of Efficacy of Short Message Service (SMS) Reminders in Improving Adherence to Laboratory Monitoring in Patients on Anticoagulation with Vitamin K antagonists(VKA): A Randomized Controlled Trial.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2025Article
- Real-Time Imaging of Platelet-Initiated Plasma Clot Formation and Lysis Unveils Distinct Impacts of Anticoagulants.Thrombosis and haemostasis · 2025Article
- Pathological Study of a Case of Catastrophic Antiphospholipid Syndrome in a Patient With Gastrointestinal Bleeding.Cureus · 2025Article
- The New Occurrence of Antiphospholipid Syndrome in Severe COVID-19 Cases with Pneumonia and Vascular Thrombosis Could Explain the Post-COVID Syndrome.Biomedicines · 2025Article
- Antiphospholipid Syndrome: A Comprehensive Clinical Review.Journal of clinical medicine · 2025Review
- Understanding artificial intelligence in critical care: opportunities, risks, and practical applications.Critical care science · 2025Review
- Trousseau syndrome: management of refractory VTE.Hematology. American Society of Hematology. Education Program · 2024Review
- Comparing clinical outcomes of vitamin K antagonists vs non-vitamin K antagonists in anticoagulant therapy for mesenteric venous thrombosis.Journal of vascular surgery. Venous and lymphatic disorders · 2024Article
- Catastrophic Antiphospholipid Syndrome: A Review of Current Evidence and Future Management Practices.Cureus · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by the persistent positivity of antiphospholipid antibodies (aPLA) together with thrombosis or obstetrical complications. Despite their recognized predominant role, aPLA are not sufficient to induce the development of thrombosis and a second hit has been proposed to be necessary. The mainstay of treatment of APS is anticoagulant therapy. However, its optimal intensity in different presentations of the disease remains undefined. Moreover, decision on which patients with aPLA would benefit from an antithrombotic prophylaxis and its optimal intensity are challenging because of the lack of stratification tools for the risk of thrombosis. Finally, decision on the optimal type of anticoagulant drug is also complex because the central pathway responsible for the development of thrombosis is so far unknown and should be carried out on an individual basis after a careful evaluation of the clinical and laboratory features of the patient. This review addresses the epidemiology, physiopathology, diagnosis and management of thrombosis and obstetrical complications in APS, with a special focus on the role of direct oral anticoagulants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.